본문 바로가기
대메뉴 바로가기
KAIST
Newsletter Vol.24
Receive KAIST news by email!
View
Subscribe
Close
Type your e-mail address here.
Subscribe
Close
KAIST
NEWS
유틸열기
홈페이지 통합검색
-
검색
KOREAN
메뉴 열기
BIO
by recently order
by view order
Professor Chan Beum Park, requested for joint international research by a German biotechnology enterprise.
- Bitop AG (Germany) requested a joint development of medicines for Alzheimer’s disease - The meaning of the financial support by European enterprise to the research result of domestic university. Professor Chan Beum Park (Department of Materials Science and Engineering in KAIST/ President Nam Pyo Suh) has been entrusted with a joint international research for the development of medicines for Alzheimer’s disease from Bitop AG, German biotechnology enterprise. KAIST recently agreed with Bitop AG to cooperate for a research program pursuing the development of inhibitors that inhibit the formation of plaque relevant to amyloid diseases like Alzheimer’s disease. Based on this agreement, KAIST will be provided with a financial support of sixty thousands Euro (about 74 million won) from Bitop AG. Professor Park will perform the screening of inhibitors, which are the core of the research, and KAIST will share patent rights from the research with Bitop AG. It is known that various degenerative nerve diseases like Alzheimer’s disease, Parkinson’s disease, mad cow disease, and so on arise mainly from the accumulation of pathological protein plaque termed amyloid, and environmental stress accelerates the diseases. So far, no effective remedy has been developed for amyloid diseases. Recently, the use of chemicals inhibiting the formation of amyloid has been raised as a potential remedy. Natural small stress molecules extracted from microbes growing in extreme environments like volcanic region on the bottom of the deep sea, etc. are gaining attention as an amyloid inhibitor. Professor Park found out for the first time in the world that Anti-stress materials are effective in inhibiting the formation of amyloid plaque and published that fact in several renowned European scientific journals. After that, Professor Park was requested by Bitop AG for a joint research and has studied for the development of medicines for Alzheimer’s disease using various kinds of Anti-stress materials. Professor Park said, “I’d like to grant a highly valuable meaning to this entrustment since it implies that European enterprises perceive the value of the research result by domestic universities and hope to promote research and development by providing practical financial support, etc. I wish this time’s entrustment will be a momentum to advance Korea’s research level one step higher through active joint researches with enterprises or institutes in U.S. and Europe as well as Bitop AG.” Bitop AG is a German enterprise that produces various Anti-stress materials coming from extreme-loving microbes. Currently, Anti-stress materials are being sold mainly as protein and cell protectants, cosmetic additives, health supplement, etc. Anti-stress materials extracted from microbes well growing in extreme environment of one hundred centigrade or more are expected to perform a role of inhibitors that inhibit the formation of amyloid plaque, the main factor of stress-related degenerative nerve diseases like Alzheimer’s disease, etc. Such Anti-stress materials are gaining attention as a future medicine for Alzheimer’s disease, etc.
2006.09.05
View 13113
Researchers Find Mechanism of Tumor Suppressor Genes
By Kim Tae-gyu. Staff ReporterTHE Korea Times 02-06-2004 Korean scientists continue to break new ground in fighting cancer as domestic researchers examined the mechanism of a gene which can help detect and treat various sorts of cancer. Korea Advanced Institute of Science and Technology (KAIST) Prof. Lim Dae-sik on Thursday said his team uncovered the mechanism of RASSF1A (Ras Association Domain Family 1 A), or tumor suppressor genes, for the first time in the world. The gene was widely considered to play an important role in reducing the proliferation of cancer cells, but its exact function and processes have remained unknown up to now. It is the second cancer-related breakthrough by Koreans in a week after Korea Institute of Science and Technology (KIST) Prof. Chung Hesson unveiled the oral anti-cancer drug. ``Cancer results from the failed management of cell cycles due to things like radiation. After a two-year intensive study, we found out how RASSF1A governs the cell cycle,"" Lim said. Lim added cancer is caused by abnormal cells, which continue to grow and divide out of control unlike normal cells, which die over time. Cancer cells develop into malignant tumors, eventually inflicting damaging effect on the human body. As a result, a lack of the RASSF1A indicates a high possibility of cancer and injection of it into cells is believed to help cure the deadly disease, according to Lim. Dr. Song Min-sup, who took charge of the research, said the findings will especially pave the way for the detection and treatment of lung cancer. ``The dearth of RASSF1A was reported mostly in the case of lung cancer. The new findings will provide insight into the diagnosis and cure of lung cancer from its early stages,"" Song explained. Lung cancer is a very elusive disease because it doesn"t cause symptoms in its infancy. When symptoms do occur, usually it is too late. ``We expect commercial detection kits or drugs for lung cancer in around five years after pre-clinic experimentation and two-phase clinic trials,"" Song expected. Details of the study is available in the scientific journal Nature Cell Biology in its February edition. voc200@koreatimes.co.kr
2004.03.15
View 14666
<<
첫번째페이지
<
이전 페이지
11
12
13
14
15
16
17
18
>
다음 페이지
>>
마지막 페이지 18